← All trials
NCT03551210
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 4, 2016
- Primary completion
- Dec 13, 2017
- Completion date
- Dec 26, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 342
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- R-PharmLead sponsor
- OCT Clinical TrialsCollaborator
- R-PharmStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.